A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men.

  title={A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5\% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men.},
  author={E. Olsen and D. Whiting and W. Bergfeld and Jeffrey J. Miller and M. Hordinsky and R. Wanser and Paul Zhang and B. Kohut},
  journal={Journal of the American Academy of Dermatology},
  volume={57 5},
BACKGROUND An alternative to currently marketed topical minoxidil solutions is desirable. OBJECTIVE To assess the efficacy and safety of a new 5% minoxidil topical formulation in a propylene glycol-free foam vehicle in men with androgenetic alopecia (AGA). METHODS This was a 16-week, double-blind, placebo-controlled trial of 5% minoxidil topical foam (MTF) in 352 men, 18 to 49 years old. At week 16, 143 subjects continued on an open-label phase to collect 52 weeks of safety information on 5… Expand
A Single-Centre, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Investigate the Efficacy and Safety of Minoxidil Topical Foam in Frontotemporal and Vertex Androgenetic Alopecia in Men
5% MTF twice a day promotes hair density and width in both frontotemporal and vertex regions in men with moderate stages of AGA. Expand
A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women.
Once-daily 5% MTF is noninferior and as effective for stimulating hair growth as twice-daily 2% MTS in women with androgenetic alopecia and is associated with several aesthetic and practical advantages. Expand
Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic evaluation
Five percent of topical minxidil was moderately superior to 10% topical minoxidil and placebo in increasing hair regrowth opposite to the expected, the irritation was marked for 10%topical minoxIDil. Expand
Comparative Study to Evaluate Tolerability of Topical 5% Minoxidil Novel Formulation and Alcohol-Based Conventional Solutions in Treatment of Androgenetic Alopecia in Indian Men: Randomized Double-Blind Study
Introduction Patients with androgenetic alopecia treated with alcohol-based minoxidil topical solutions often report local irritation, dryness, and redness of the scalp. We evaluate the in-useExpand
A Randomized, Controlled Pilot Trial Comparing Platelet-Rich Plasma to Topical Minoxidil Foam for Treatment of Androgenic Alopecia in Women.
  • A. Bruce, T. Pincelli, +6 authors S. Shapiro
  • Medicine
  • Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • 2019
Platelet-rich plasma is an effective treatment for hair regrowth in female AGA, although not as effective as minoxidil, and the improved quality of life responses after PRP, but not minoxido suggest a potential overall greater degree of satisfaction with PRP. Expand
A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia.
Latanoprost significantly increased hair density at 24 weeks compared with baseline and the placebo-treated area and could be useful in stimulating hair follicle activity and treating hair loss. Expand
Topical valproic acid increases the hair count in male patients with androgenetic alopecia: A randomized, comparative, clinical feasibility study using phototrichogram analysis
  • S. Jo, Hyoseung Shin, +5 authors O. Kwon
  • Medicine
  • The Journal of dermatology
  • 2014
Topical VPA increased the total hair counts of the authors' patients; therefore, it is a potential treatment option for androgenetic alopecia (AGA) and should be considered for further studies. Expand
Is Minoxidil Efficacious and Safe for the Treatment of Androgenetic Alopecia (AGA) in Men, and If So, What Is the Optimal Strength and Means of Delivery?
Minoxidil is safe and efficacious in the treatment of male AGA especially at the strength of 5% in either foam or solution preparation for twice daily use. Expand
Curcuma aeruginosa, a novel botanically derived 5α-reductase inhibitor in the treatment of male-pattern baldness: a multicenter, randomized, double-blind, placebo-controlled study
In men with hair loss in the vertex area of the scalp, the combination of 5% hexane extract of C. aeruginosa and 5% minoxidil slowed hair loss and increased hair growth. Expand
Minoxidil 2% lotion for eyebrow enhancement: A randomized, double‐blind, placebo‐controlled, spilt‐face comparative study
It is suggested that minoxidil 2% lotion is a safe and effective treatment for eyebrow hypotrichosis. Expand


A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men.
Data from a patient questionnaire demonstrated that 5% topical minoxidil helped improve patients' psychosocial perceptions of hair loss in men with androgenetic alopecia as well as boosting hair regrowth in this 48-week trial. Expand
Topical minoxidil in early male pattern baldness.
Treatment of subjects with topical minoxidil for 4 months resulted in a statistically significant increase in terminal hair growth in comparison with placebo therapy, and subjects initially treated with placebo, when crossed over to topical minxidil showed a significant increase to the number of terminal hairs. Expand
Androgenetic alopecia in the female. Treatment with 2% topical minoxidil solution.
Topical minoxidil was significantly more effective than placebo in the treatment of female androgenetic alopecia and the number of nonvellus hairs regrown was increased. Expand
Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group.
In men with male pattern hair loss, finasteride 1 mg/d slowed the progression of hair loss and increased hair growth in clinical trials over 2 years. Expand
Topical minoxidil therapy in hereditary androgenetic alopecia.
The most notable indicators for regrowth of hair were the number of indeterminate hairs initially present, the duration of baldness, and the size of the balding area. Expand
This study focuses on the treatment of hair loss in women withAndrogenetic alopecia, which begins as a diffuse and progressive thinning of the frontoparietal area of the scalp in women. Expand
Studies of common baldness in the stumptailed macaque. IV. In vitro metabolism of testosterone in the hair follicles.
The uptake and catabolism of tritiated testosterone by hair follicles from both the bald and hairy regions of the scalp and back of stumptailed macaques were studied in vitro, and the first biochemical finding that gives some characterization to hair follicle from the bald scalp is found. Expand
Nonhuman Primate Model of Baldness
  • H. Uno
  • Biology, Medicine
  • International journal of dermatology
  • 1982
Baldness is not solely an affliction of mankind. Nonhuman primates, including some aging chimpanzees, most adult stumptailed macaques and South American Red Uacari, show typical baldness similar toExpand
The discovery by F. d'Herelle of the phenomenon of bacteriophagia in 1916 and his subsequent development of the subject are well known and many other investigators have reported on laboratory and clinical investigations confirming these observations. Expand
Photographic documentation of hair growth in androgenetic alopecia.
The challenge of useful serial photographic documentation of hair loss can be met by using a regimented approach at each photographic session. Patient outcomes that are better documented allow forExpand